Cargando…

Evolocumab to reduce cardiovascular events: results of the (FOURIER) multinational trial

Detalles Bibliográficos
Autores principales:	Shah, Syed Raza, Uddin, Mohd Faisal, Lateef, Noman, Dharani, Amin Muhammad, Shahnawaz, Waqas, Kazi, Ahmed Nabeel, Shah, Syed Arbab
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2017
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5538222/ https://www.ncbi.nlm.nih.gov/pubmed/28808518 http://dx.doi.org/10.1080/20009666.2017.1340732

Ejemplares similares

Bioresorbable vascular scaffold versus metallic stent in percutaneous coronary intervention: results of the AIDA trial
por: Shah, Syed Raza, et al.
Publicado: (2017)

Use of dark chocolate for diabetic patients: a review of the literature and current evidence
por: Shah, Syed Raza, et al.
Publicado: (2017)

Canakinumab and cardiovascular outcomes: results of the CANTOS trial
por: Shah, Syed Raza, et al.
Publicado: (2018)

Effects of Evolocumab on Cardiovascular Events
por: Mikhail, Nasser
Publicado: (2017)

Canagliflozin and Cardiovascular disease- results of the CANVAS trial
por: Shah, Syed Raza, et al.
Publicado: (2018)

Using left ventricular assist devices in advanced heart failure patients
por: Shah, Syed Raza, et al.
Publicado: (2018)

Atrial fibrillation and heart failure- results of the CASTLE-AF trial
por: Shah, Syed Raza, et al.
Publicado: (2018)

Restoring mortality data in the FOURIER cardiovascular outcomes trial of evolocumab in patients with cardiovascular disease: a reanalysis based on regulatory data
por: Erviti, Juan, et al.
Publicado: (2022)

Evolocumab’s Long-Term Mortality Risk Unclear Due to Shortened Follow-Up of FOURIER
por: van Bruggen, Folkert H., et al.
Publicado: (2021)

The effect of evolocumab alone and in combination with atorvastatin on atherosclerosis progression and TLRs expression
por: Saud, Ali, et al.
Publicado: (2023)

Cost-Effectiveness Analysis of Evolocumab in Adult Patients with Atherosclerotic Cardiovascular Disease in Canada
por: Grégoire, Jean, et al.
Publicado: (2022)

Cardiovascular Events in Patients with Thyroid Storm
por: Waqar, Zainulabedin, et al.
Publicado: (2021)

Retargeting the management of hypercholesterolemia – focus on evolocumab
por: Colletti, Alessandro, et al.
Publicado: (2016)

Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on the number needed to treat
por: Wang, Hong-Fei, et al.
Publicado: (2022)

Effect of Sociodemographic Variables and Other Factors on the Usage of Different Doses of Aspirin in Postmyocardial Infarction Patients: A Cross-sectional Study
por: Shah, Syed Raza, et al.
Publicado: (2018)

Profile of evolocumab and its potential in the treatment of hyperlipidemia
por: Cicero, Arrigo FG, et al.
Publicado: (2015)

Efficacy of Evolocumab in Monogenic vs Polygenic Hypercholesterolemia
por: Lee, Timothy, et al.
Publicado: (2019)

Maculopapular Exanthema After the Second Dose of Evolocumab
por: Ghernautan, Victoria, et al.
Publicado: (2021)

Cost‐Effectiveness of LDL‐C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States
por: Gandra, Shravanthi R., et al.
Publicado: (2016)

PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab
por: Blom, Dirk J, et al.
Publicado: (2016)

Influence of Renal Function on Evolocumab Exposure, Pharmacodynamics, and Safety
por: Lee, Edward, et al.
Publicado: (2019)

Atrial Fibrillation as a Possible Adverse Reaction to Evolocumab
por: Abdelmaseih, Ramy, et al.
Publicado: (2021)

Evolocumab loaded Bio-Liposomes for efficient atherosclerosis therapy
por: Li, Zhenxian, et al.
Publicado: (2023)

Topical vasodilator response in skeletonized internal mammary artery: Is there really a difference?
por: Shah, Syed Raza, et al.
Publicado: (2017)

Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor
por: Kasichayanula, Sreeneeranj, et al.
Publicado: (2018)

Patient adherence, compliance, and perspectives on evolocumab for the management of resistant hypercholesterolemia
por: Kosmas, Constantine E, et al.
Publicado: (2018)

A Sudden Onset of Severe Thrombocytopenia While Using Evolocumab
por: Inoue, Ikuo, et al.
Publicado: (2020)

Is Deprescription of Ezetimibe Safe in Familial Hypercholesterolemia Patients Taking Evolocumab?
por: Hang, Shyann, et al.
Publicado: (2021)

Evolocumab Effects on Lipoproteins, Measured by High-Performance Liquid Chromatography
por: Masuda, Daisaku, et al.
Publicado: (2020)

EVOLOCUMAB TREATMENT FAILURE FOLLOWING COVID-19 MRNA VACCINATION
por: Park, Byung Joon, et al.
Publicado: (2022)

A Systematic Review of PCSK9 Inhibitors Alirocumab and Evolocumab
por: McDonagh, Marian, et al.
Publicado: (2016)

Novel biosynthesis, characterization and bio-catalytic potential of green algae (Spirogyra hyalina) mediated silver nanomaterials
por: Abdullah, et al.
Publicado: (2022)

The Effect of the PCSK9 Inhibitor Evolocumab on Aldosterone Secretion among High Cardiovascular Risk Patients: A Pilot Study
por: Izkhakov, Elena, et al.
Publicado: (2021)

Lipid lowering effects and safety of evolocumab in Chinese patients at very high cardiovascular risk: a single-center study
por: Chai, Meng, et al.
Publicado: (2023)

Sensitive Detection of Pharmaceutical Drugs and Metabolites in Serum Using Data-Independent Acquisition Mass Spectrometry and Open-Access Data Acquisition Tools †
por: Shah, Syed Muhammad Zaki, et al.
Publicado: (2022)

Clinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reduction
por: Henry, Courtney A, et al.
Publicado: (2016)

Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia
por: Rosenson, Robert S., et al.
Publicado: (2016)

Clinical utility of evolocumab in the management of hyperlipidemia: patient selection and follow-up
por: Dixon, Dave L, et al.
Publicado: (2017)

Clinical Evaluation Of Evolocumab For The Treatment Of Homozygous Familial Hypercholesterolemia In Chinese Patients
por: Huang, Chin-Chou, et al.
Publicado: (2019)

Sudden Fall in the Lipid-Lowering Effect of Evolocumab: The Butler Is Not Always Guilty
por: Fogacci, Federica, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ulejq7s81j82s9smnba8l6c0tu